# | Title | Journal | Year | Citations |
---|
1 | Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2015 | 5,183 |
2 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet, The | 2017 | 1,749 |
3 | Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes | Nature Medicine | 2015 | 1,592 |
4 | Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer | Nature Medicine | 2018 | 1,071 |
5 | Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial | Lancet, The | 2014 | 1,068 |
6 | Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA | PLoS ONE | 2015 | 580 |
7 | Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study | Journal of Clinical Oncology | 2006 | 560 |
8 | Gastric adenocarcinoma | Nature Reviews Disease Primers | 2017 | 409 |
9 | Progression of Monoclonal Gammopathy with Undetermined Significance to Multiple Myeloma Diagnosed by Kidney Biopsy: A Case Report | Case Reports in Nephrology and Dialysis | 2015 | 375 |
10 | Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study | Lancet Oncology, The | 2018 | 370 |
11 | Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial | Lancet Oncology, The | 2015 | 353 |
12 | The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma | Blood | 2007 | 283 |
13 | A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) | Annals of Oncology | 2015 | 275 |
14 | An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach | International Journal of Radiation Oncology Biology Physics | 2005 | 268 |
15 | Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma | Cancer Discovery | 2018 | 248 |
16 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) | Annals of Oncology | 2019 | 230 |
17 | Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study | European Journal of Cancer | 2013 | 218 |
18 | Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer | Journal of Thoracic Oncology | 2018 | 203 |
19 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial | Lancet, The | 2021 | 177 |
20 | Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2007 | 175 |
21 | Linking transcriptional and genetic tumor heterogeneity through allele analysis of single-cell RNA-seq data | Genome Research | 2018 | 172 |
22 | Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing | Nature Communications | 2014 | 166 |
23 | Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors | Journal of Thoracic Oncology | 2013 | 163 |
24 | Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer | Journal of Thoracic Oncology | 2015 | 163 |
25 | Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus–Associated Gastric Carcinoma | Gastroenterology | 2010 | 162 |
26 | Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients | British Journal of Cancer | 2009 | 159 |
27 | Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma | Hepatology | 2013 | 159 |
28 | Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study | Lancet Oncology, The | 2021 | 157 |
29 | EGFR TKI combination with immunotherapy in non-small cell lung cancer | Expert Opinion on Drug Safety | 2017 | 156 |
30 | Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial | Cancer Discovery | 2019 | 155 |
31 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Gastric Cancer | 2020 | 155 |
32 | A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆ | Annals of Oncology | 2021 | 153 |
33 | Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapy | European Journal of Cancer | 2005 | 152 |
34 | Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel | Clinical Cancer Research | 2019 | 152 |
35 | Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications | Annals of Surgical Oncology | 2010 | 147 |
36 | Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer | Journal of Thoracic Oncology | 2009 | 145 |
37 | Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy | Nature Genetics | 2018 | 145 |
38 | Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma | Clinical Cancer Research | 2019 | 142 |
39 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Annals of Oncology | 2020 | 138 |
40 | Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome | Annals of Hematology | 2007 | 137 |
41 | Lung adenocarcinoma promotion by air pollutants | Nature | 2023 | 135 |
42 | Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) | Oncotarget | 2016 | 134 |
43 | The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors | Clinical Cancer Research | 2019 | 134 |
44 | Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study | Biology of Blood and Marrow Transplantation | 2008 | 133 |
45 | ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation | British Journal of Cancer | 2008 | 132 |
46 | Chemotherapy for pulmonary large cell neuroendocrine carcinoma: Similar to that for small cell lung cancer or non-small cell lung cancer? | Lung Cancer | 2012 | 130 |
47 | Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling | Annals of Surgical Oncology | 2013 | 130 |
48 | Bifidobacterium bifidum strains synergize with immune checkpoint inhibitors to reduce tumour burden in mice | Nature Microbiology | 2021 | 130 |
49 | Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study | Haematologica | 2016 | 129 |
50 | ADAR-Mediated RNA Editing Predicts Progression and Prognosis of Gastric Cancer | Gastroenterology | 2016 | 127 |